We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.51 | -1.62% | 91.57 | 91.56 | 91.58 | 94.03 | 91.33 | 93.99 | 329,419 | 10:58:38 |
From May 2022 to May 2024
By Pierre Bertrand
Sanofi SA on Wednesday said it was discontinuing its global clinical development program for breast-cancer treatment amcenestrant.
The French pharmaceutical company said the decision to halt the program for the treatment, which targets a type of advanced or metastatic breast cancer, was based on the interim analysis of its Phase 3 Ameera-5 trial.
An independent monitoring committee found that the drug didn't satisfy the requirements for continued study and recommended stopping the trial, Sanofi said.
The company also said that all other studies involving the drug, including in early-stage breast cancer, will be discontinued. Data related to the drug will be reviewed and shared with the scientific community in the future, Sanofi said.
Sanofi said in March that a Phase 2 clinical trial evaluating the drug's performance failed.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
August 17, 2022 02:24 ET (06:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
